The Deal: Gilead Sciences agreed to acquire Arcellx for $115/share plus a $5 CVR, representing a 79% premium to Friday's close.

The Asset: The deal gives Gilead full control of anito-cel, a BCMA-directed CAR-T therapy showing a 96% response rate in relapsed/refractory multiple myeloma.

Timeline: The FDA's PDUFA date is December 23, 2026. Gilead already owned 11.5% of Arcellx; the acquisition is expected to close in Q2 2026.

The Policy: The FDA released draft guidance establishing a "Plausible Mechanism Pathway" for individualized therapies targeting ultra-rare genetic diseases.

Why It Matters: The framework allows approval based on "one well-controlled investigation" when randomized controlled trials aren't feasible, heavily favoring genome editing and RNA-based therapies.

Executive Impact: This dramatically lowers the clinical evidence burden for bespoke N-of-1 style treatments.

The Deal: Vir Biotechnology and Astellas announced a global partnership for VIR-5500, a PSMA-targeting dual-masked T-cell engager.

The Terms: Vir receives $335M upfront ($240M cash + $75M equity at a 50% premium + $20M near-term milestone) with up to $1.37B in additional milestones. U.S. profits will be split 50/50, with Phase 3 planned for 2027.

Data: Updated Phase 1 results for VIR-5500 in late-line mCRPC showed an 82% PSA50 decline and 45% ORR in ≥3,000 µg/kg Q3W cohorts, with no dose-limiting toxicities. Full presentation at ASCO GU on Thursday.

Data: Reported updated Phase 1/1b ARC-20 data for casdatifan (HIF-2α inhibitor) in metastatic ccRCC. The 100mg QD tablet cohort achieved 15.1 months median PFS and a 45% confirmed ORR at 17.9 months follow-up.

Transaction: Fortress Biotech subsidiary Cyprium agreed to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $205M. The voucher was granted in January for the approval of Zycubo (Menkes disease).

Clearance: Received FDA IND clearance for DARE-HPV, a vaginal insert formulation of lopinavir/ritonavir for persistent high-risk HPV infection. The Phase 2 study is backed by a $10M ARPA-H contract.

Progress: Completed patient dosing in Cohort B2 (1.2mg/kg) for its polycystic kidney disease program, successfully transitioning the asset from healthy volunteers into the target patient population.

Partnership: Entered a $120M collaboration to discover novel therapeutics for genetic epilepsies using Quiver's AI-driven CNS drug discovery platform.

Supply Chain: Signed a collaboration agreement for iodine extraction feasibility studies in Oklahoma. Voyageur is eligible for up to $2.35M in milestone funding as it expands its vertically integrated contrast media portfolio.

Funding: Opened applications for up to $1M per company in non-dilutive support for Australian biotech translation and commercialization. Applications close March 30, 2026.